States are experiencing a huge rise in the number of people without health insurance in the wake of mass layoffs resulting from the COVID-19 pandemic and are seeking strategies to protect them from high prescription drug prices. The uninsured are sometimes the only consumers left paying the full list price for a drug, while the […]
https://nashp.org/wp-content/uploads/2018/10/st-rx-admin-action-image-shutterstock_10_15_2018.jpg37445616Melanie Felicianohttps://nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2020-04-20 20:52:302020-04-21 13:10:37State Rx Purchasing Pool Buy-In Model Gives the Unemployed Access to Discounted Drugs
Last week, a California Court of Appeal lifted an injunction that prevented the state from sharing drug manufacturers’ advance notice of drug price increases. The ruling was a win for states working to advance drug price transparency in the face of manufacturers’ sometimes overly-broad claims of trade secret protection for their prices.
https://nashp.org/wp-content/uploads/2018/10/st-rx-admin-action-image-shutterstock_10_15_2018.jpg37445616Melanie Felicianohttps://nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2020-04-13 19:31:112020-04-17 14:25:58Court Rules California Can Share Advance Notice of Rx Price Hikes
More than 50 major health systems, including hospitals in every state, have joined forces to create Civica Rx, a nonprofit drug manufacturer that produces affordable, sustainable supplies of certain generic medications – a mission made more critical than ever by generic shortages related to the COVID-19 pandemic.
https://nashp.org/wp-content/uploads/2020/03/oud-pills.jpg232243Melanie Felicianohttps://nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2020-04-13 14:57:382020-04-17 14:27:46How States Can Join Civica Rx and Blue Cross Blue Shield’s Partnership for an Affordable, Sustainable Supply of Generics
Absent sufficient evidence from clinical trials that proves a variety of drugs are effective against COVID-19, many states are providing guidance to limit their use and have begun monitoring them for price increases and shortages. Building on experience from states’ drug price transparency laws, policymakers now have tools to track these drug costs and identify […]
https://nashp.org/wp-content/uploads/2018/10/st-rx-admin-action-image-shutterstock_10_15_2018.jpg37445616Melanie Felicianohttps://nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2020-04-06 12:05:512020-04-16 18:54:11States with Transparency Laws Monitor Prices of Potential COVID-19 Drug Treatments
https://nashp.org/wp-content/uploads/2019/01/rx-bill-calculator-shutterstock_10_15_2018.jpg37445616Melanie Felicianohttps://nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2020-03-30 18:14:552020-04-16 17:41:04States Act to Protect Consumers against Unproven COVID-19 Drugs and Safeguard Supplies as FDA Approves Limited Use
https://nashp.org/wp-content/uploads/2019/06/NASHP-Logo.png00NASHP Staffhttps://nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngNASHP Staff2020-03-17 12:19:082020-04-16 12:22:52Webinar: BCBS Plans and Civica Rx Partner to Produce Lower-Cost Generic Drugs - Opportunities for States
https://nashp.org/wp-content/uploads/2019/01/rx-bill-calculator-shutterstock_10_15_2018.jpg37445616Melanie Felicianohttps://nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2020-03-09 17:46:262020-03-10 13:02:34NASHP Responds to Proposed, Landmark Federal Drug Importation Rule: Changes Needed
Maryland’s first-in-the-nation Prescription Drug Affordability Board (PDAB), enacted last year, has the authority to set upper payment limits for certain high-cost drugs purchased by state and local government. The board is also tasked with proposing a plan to extend upper payment limits to all purchasers in the state. This Q&A provides an update on Maryland’s […]